Regeneron’s CRL For High-Dose Eylea Benefits Roche, Vabysmo

 
• By Joseph Haas

Although the US FDA complete response letter only cites third-party manufacturing issues, analysts say the delayed approval of 8mg Eylea could continue a competitive advantage for Vabysmo into 2024.

Falling behind
FDA delay may cause Regeneron to cede more ground to Roche's Vabysmo • Source: Shutterstock

More from Strategy

More from Business